scholarly journals P-25 Single-institution experience of total neoadjuvant therapy for locally advanced rectal cancer: Long-term results

2020 ◽  
Vol 31 ◽  
pp. S97
Author(s):  
C. Spatola ◽  
G. Privitera ◽  
R. Milazzotto ◽  
R. Liardo ◽  
V. Salamone ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Neoadjuvant Therapy ◽  
Locally Advanced ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer ◽  
Long Term Results ◽  
Single Institution ◽  
Total Neoadjuvant Therapy

scholarly journals The Oncologic Efficacy and Long-term Survival Outcomes of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Systemic Review and Meta-Analysis

2021 ◽  
Author(s):  
Gan Bin Li ◽  
Yu Tao ◽  
Zhen Jun Wang ◽  
Zhai Wei Zhai ◽  
Jia-Gang Han
Keyword(s):  
Rectal Cancer ◽  
Neoadjuvant Therapy ◽  
Meta Analysis ◽  
Locally Advanced ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer ◽  
Term Survival ◽  
Long Term Survival ◽  
Total Neoadjuvant Therapy

Abstract Purpose To evaluate the pooled oncologic efficacy of total neoadjuvant therapy for locally advanced rectal cancer patients using meta-analysis method.Method To evaluate the pooled effects of total neoadjuvant therapy in terms of exact oncologic efficacy and long-term survival outcomes, a systemic literature search of PubMed, Embase, China Biology Medicine and WanFang Database was performed.Results A total of 15 studies including 4091 patients were finally identified. The pooled analysis revealed that total neoadjuvant therapy significantly increased the rates of T-downstaging (OR=2.16, 95% CI:1.63~2.87, P<0.00001), pathologic complete response (OR=1.90, 95% CI:1.60~2.27, P<0.00001) and R0 resection (OR=1.44, 95% CI: 1.07~1.93, P=0.01) with a comparable safety profile. Most importantly, patients received total neoadjuvant therapy had a superior overall survival rate compared to standard neoadjuvant chemoradiotherapy (HR=0.74, 95% CI: 0.62~0.89, P=0.001).Conclusion Patients with locally advanced rectal cancer can be managed with total neoadjuvant therapy with a superior short-term oncologic efficacy and long-term survival benefits.

Neoadjuvant CAPOX and bevacizumab alone for locally advanced rectal cancer: long-term results from the N-SOG 03 trial

2018 ◽  
Vol 24 (4) ◽  
pp. 403-410 ◽  
Author(s):  
Akihiro Tomida ◽  
◽  
Keisuke Uehara ◽  
Kazuhiro Hiramatsu ◽  
Atsuyuki Maeda ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Locally Advanced ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer ◽  
Long Term Results
Sign in / Sign up

Export Citation Format

Share Document